Crestone

Crestone, Inc. is a biopharmaceutical company developing novel small molecule drugs designed to combat serious bacterial infections. The firm focuses on creating new drug candidates with entirely novel mechanisms of action, addressing a critical need for advanced treatments against pathogens such as C. difficile and non-tuberculous mycobacteria. Its clinical-stage pipeline is dedicated to pioneering innovative therapeutic approaches where current treatments may be insufficient.

Founded in 2015 by Thale Jarvis and John Rohloff, Crestone, Inc. emerged from an understanding of the increasing global threat posed by antibiotic resistance and the imperative for new antimicrobial agents. Their collective scientific and drug development expertise forms the bedrock of the company's approach, aiming to invent solutions that offer fundamentally different ways to tackle persistent and emerging bacterial threats.

Crestone's work ultimately serves patients worldwide afflicted with severe bacterial infections. The company’s vision is to advance global patient health by successfully developing and bringing to market life-saving antibiotics. It strives to establish a robust profile of pharmacology, tolerability, and efficacy for its drug candidates, positioning them to significantly improve patient outcomes in the ongoing battle against infectious diseases.